AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn) Process for generating a metal complexed agent, comprising:

contacting a solid phase bound organic conjugate represented by formula (I) with $[M(H_20)_3(CO)_3]^{n+}$,



(I)

wherein:

the sphere is a solid phase support;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule,

wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu); and

n is 1, 2 or 3.

2. (Withdrawn) Process according to claim 1, wherein L is a linker selected from the group consisting of phenyl, vinyl, alkyl, allyl, aryl, and other non-aliphatic and aliphatic groups.

3. (Withdrawn) Process according to claim 2, wherein L is substituted with an electron withdrawing group selected from OR, R and $N(R)_2$, wherein R is an aliphatic or arylic group.

4. (Withdrawn) Process according to claim 1, wherein L is as shown in formula II:



(II)

wherein X_1 is C or O, and each of X_2 is an electron withdrawing substituent.

5. (Withdrawn) Process according to claim 1, wherein at least one of R_1 and R_2 is selected from the group consisting of



$R3-NH_2$

wherein R3 is a tertiary amine, or an aliphatic chain containing 1, 2 or 3 carbons.

6. (Withdrawn) Process according to claim 1, wherein at least one of R_1 and R_2 is an aliphatic or aromatic substituent.

7. (Withdrawn) Process according to claim 1, further comprising forming a coordinate bond between $[M(H_20)_3(CO)_3]^{n+}$ and a tertiary amine nitrogen atom of the solid phase bound organic conjugate, and releasing a metal complexed agent thus formed.

8. (Withdrawn) Process according to claim 1, wherein M is selected from the group consisting of ^{99m}Tc, ^{186}Re and ^{188}Re.

9. (Withdrawn) Process according to claim 1, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.

10. (Withdrawn) Process according to claim 1, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

11. (Cancelled).

12. (Withdrawn) Process according to claim 1, wherein the process is performed at a pH that is in the range of about 6.0-11.0.

13. (Withdrawn) Process according to claim 1, wherein the process is performed at a temperature in the range of about 40-100 C.

14. (Cancelled).

15. (Previously Presented) A solid phase bound organic conjugate represented by formula (I)



(I)

wherein the sphere is a solid phase support;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

16. (Previously Presented) A solid phase bound organic conjugate according to claim 15, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.

17. (Previously Presented) A solid phase bound organic conjugate according to claim 15, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

18-19. (Cancelled).

20. (Previously Presented) A kit for the preparation of a diagnostic or therapeutic pharmaceutical composition, the kit comprising:

a container; and

a molecule of formula (I),



(I)

wherein the sphere is a solid phase;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

in which the reaction with a solution of $[M(H_20)_3(CO)_3]^{n+}$ can take place.

21. (Original) Kit as claimed in claim 20, wherein the container is a vessel or column.

22. (Previously Presented) Kit as claimed in claim 20, further comprising a solution of $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

23. (Previously Presented) Kit as claimed in claim 20, further comprising reagents for preparation of $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

24. (Original) Kit as claimed in claim 20, further comprising a facility for filtration.

25. (New) The solid phase bound organic conjugate according to claim 15, wherein the organic conjugate is in contact with a solution of $[M(H_20)_3(CO)_3]^{n+}$,

wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu); and

n is 1, 2 or 3.

26. (New) The solid phase bound organic conjugate according to claim 25, wherein M is ^{99m}Tc and n is 1.

27. (New) The solid phase bound organic conjugate according to claim 15, wherein at least one of R_1 and R_2 is selected from the group consisting of:



, , , and

wherein R3 is directly attached to the tertiary amine or is an aliphatic chain containing between 1 and 3 carbons.

28. (New) The solid phase bound organic conjugate according to claim 16, wherein the pharmaceutically active small molecule is biotin.

29. (New) The solid phase bound organic conjugate according to claim 15, wherein L is a linker selected from the group consisting of phenyl, vinyl, alkyl, allyl, aryl, and other non-aliphatic and aliphatic groups.

30. (New) The solid phase bound organic conjugate according to claim 29, wherein L is substituted with an electron withdrawing group selected from OR, R and $N(R)_2$, wherein R is an aliphatic or arylic group.

31. (New) The solid phase bound organic conjugate according to claim 15, wherein L is as shown in formula II:



(II)

wherein X_1 is C or O, and each of X_2 is an electron withdrawing substituent.